Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

548
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
548

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary prevention of Parkinson's disease: proceedings, the 8C's and a position statement from the Parkinson's disease prevention think tank.

NPJ Parkinson's disease·2026
Same author

Alzheimer's disease risk prediction from clinical and social determinants of health: a machine learning cohort study in UK Biobank.

BMJ health & care informatics·2026
Same author

Impact of Sleep Quality on Gait Variability: Pilot Cohort Study.

JMIR aging·2026
Same author

Acceptability of Technologies to Support Early Dementia Detection: Qualitative Study With the Boston University Alzheimer's Disease Center Cohort.

Journal of medical Internet research·2026
Same author

The myth of digital biomarkers in Alzheimer's disease: how to make them a reality.

Current opinion in psychiatry·2026
Same author

Gender differences in informal caregiving costs and burden in Alzheimer disease: a multinational cross-sectional analysis.

BMC public health·2026

Related Experiment Video

Updated: Nov 13, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.5K

Enhancing magnetic resonance imaging-driven Alzheimer's disease classification performance using generative

Xiao Zhou1,2, Shangran Qiu1,3, Prajakta S Joshi4,5

  • 1Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 E. Concord Street, Evans 636, Boston, MA, 02118, USA.

Alzheimer'S Research & Therapy
|March 15, 2021
PubMed
Summary

Generative adversarial networks (GAN) enhance Alzheimer's disease (AD) classification by improving magnetic resonance imaging (MRI) quality. This modified GAN approach boosts diagnostic accuracy using higher-field strength (3T) MRI data.

Keywords:
Alzheimer’s diseaseDeep learningFully convolutional networkGenerative adversarial networkMagnetic field strengthMagnetic resonance imaging

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

529
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.3K

Related Experiment Videos

Last Updated: Nov 13, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.5K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

529
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.3K

Area of Science:

  • Neuroimaging
  • Artificial Intelligence
  • Medical Diagnostics

Background:

  • Generative adversarial networks (GAN) show potential for improving image quality.
  • The application of GANs to augment image-based classification, particularly in neuroimaging for Alzheimer's disease (AD), is not fully explored.
  • Magnetic resonance imaging (MRI) at different field strengths presents unique characteristics for diagnostic analysis.

Purpose of the Study:

  • To evaluate if a modified GAN can enhance Alzheimer's disease (AD) classification performance.
  • To investigate the ability of GANs to learn from multi-field strength MRI scans.
  • To improve the quality of MRI scans for better diagnostic outcomes.

Main Methods:

  • T1-weighted brain MRI scans from 151 ADNI participants (1.5-T and 3-T) were used to construct a GAN model.
  • A three-dimensional fully convolutional network (FCN) was trained using GAN-generated 3-T images (3T*) to predict AD status.
  • Image quality was assessed using signal-to-noise ratio (SNR), BRISQUE, and NIQE; validation was performed on AIBL and NACC datasets.

Main Results:

  • The 3T*-based FCN classifier demonstrated improved performance compared to the 1.5-T FCN model across ADNI, AIBL, and NACC datasets.
  • Mean area under the curve (AUC) increased from 0.907 to 0.932 (ADNI), 0.934 to 0.940 (AIBL), and 0.870 to 0.907 (NACC).
  • Generated 3T* images showed consistently higher quality than 1.5-T images based on SNR, BRISQUE, and NIQE metrics.

Conclusions:

  • GAN frameworks can be constructed to augment AD classification performance.
  • This study provides a proof of principle for using GANs to improve MRI image quality for AD diagnosis.
  • The findings suggest GANs are a promising tool for enhancing neuroimaging-based disease classification.